|  | 
  
    | April 12, 2006: Embolic Protection and Thrombectomy: If Yes, When, Who and How |  
    | This video is sponsored by the Duke Clinical Medical Series. 
 Topics include:
 * Case Presentation
 * Embolic Protection and Thrombectomy If Yes: When, Who, and How?
 * Outline
 * Microembolization During Interventions (ACS)
 * SAFER Angiographic Predictors % Graft Diseased, Plaque Volume, Rx
 * Outline
 * Embolic Protection Devices
 * SAFER Primary Endpoint 30-day MACE (N = 801)
 * EMERALD: Infarct Size By Tc-99m SPECT (Infarct Size; % LV)
 * TriActiv System Key Components
 
 The moderator, Peter Berger, MD, has indicated that he receives research/grant support
 from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
 advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
 symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
 serves as Medical Director and has equity with Lumen, Inc.
 
 The guest faculty, James Hermiller, MD, has indicated that he receives research/grant
 support from Cordis/Johnson & Johnson, Medtronic, BSC, and Guidant. He is a consultant
 for BSC, Guidant, and Anhoff.
 
 n/a
 
 
 
 
 |  |  |